Sensei Biotherapeutics, Inc. (SNSE)

Market Cap	11.38M
Revenue (ttm)	n/a
Net Income (ttm)	-29.03M
Shares Out	1.26M
EPS (ttm)	-23.08
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,809
Open	9.00
Previous Close	9.27
Day's Range	9.00 - 9.07
52-Week Range	5.00 - 17.40
Beta	0.27
Analysts	Strong Buy
Price Target	86.67 (+859.8%)
Earnings Date	Aug 5, 2025

About SNSE

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company’s Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 2021
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: SNSE
• Website: https://www.senseibio.com

Analyst Summary

According to 3 analysts, the average rating for SNSE stock is "Strong Buy." The 12-month stock price target is $86.67, which is an increase of 859.80% from the latest price.

Price Target

$86.67

(859.80% upside)

Analyst Consensus: Strong Buy